Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .

NCT04105439 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2021-01-13

No results posted yet for this study

Summary

The purpose of the study is to determine whether plasma levels of the soluble urokinase plasminogen activator(suPAR) can serve as a blood-based biomarker for diagnosis of Behçet's disease and its correlation with disease activity.

Conditions

  • Behçet Disease

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2021-11-01
Completion
2021-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04105439 on ClinicalTrials.gov